DePuy Synthes Receives FDA Clearance for TELIGEN™ System
prnewswire.com
business
2022-10-20 11:32:00

New MedTech Advancement Brings First-of-Its-Kind Technology to Spine Surgeons, Delivering Advanced Visualization and User-Centric Procedural Control RAYNHAM, Mass., Oct. 20, 2022 /PRNewswire/ -- Today, Johnson & Johnson MedTech* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson**, has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its TELIGEN™ System, an integrated technology platform that enables minimally invasive surgical transforaminal lumbar interbody fusion (MIS-TLIF) procedures through digital tools for visualization and access.
